Drug Population, Risk Should Receive Greater Attention In R&D – Wyeth VP
Executive Summary
Pharmaceutical R&D should focus more on targeting appropriate populations and risk assessment rather than immediate blockbuster potential, Wyeth VP-Project & Portfolio Management Richard Heaslip suggested